Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective.

Internal Medicine Journal
Sarah A HitchenBu B Yeap

Abstract

Recent cardiovascular safety trials on sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated the significant cardiovascular and renal benefits of these medications. Diabetes organisations have revised their medication guidelines to include a focus on disease outcomes for cardiovascular disease, heart failure and renal disease. This article summarises latest evidence, guideline recommendations and current Australian Pharmaceutical Benefits Scheme requirements.

References

Jul 3, 2015·Therapeutic Advances in Endocrinology and Metabolism·Sri Harsha Tella, Marc S Rendell
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Aug 3, 2016·JAMA : the Journal of the American Medical Association·Kenneth B MarguliesUNKNOWN NHLBI Heart Failure Clinical Research Network
Apr 14, 2017·The New England Journal of Medicine·Aidin RawshaniSoffia Gudbjörnsdottir
Mar 2, 2018·Therapeutic Advances in Endocrinology and Metabolism·Wesley NufferJennifer M Trujillo
Jul 12, 2018·Current Diabetes Reviews·Robin L Black, Courtney Duval
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Aug 1, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·N S R LanB B Yeap

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.